Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Coya Therapeutics, Inc. - Common Stock
(NQ:
COYA
)
4.750
-0.100 (-2.06%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 12, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Coya Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients
January 08, 2026
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD)
January 05, 2026
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
December 23, 2025
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS
December 09, 2025
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences
November 25, 2025
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Reports Third Quarter Financial Results and Provides a Corporate Update
November 12, 2025
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Announces That Its Combination LD IL-2/GLP-1 RA Candidate (COYA 303) Demonstrated Potent Systemic and Brain Anti-Inflammatory Efficacy In Vivo
November 04, 2025
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriter’s Option to Purchase Additional Shares
October 27, 2025
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Announces Pricing of $20 Million Upsized Public Offering of Common Stock
October 24, 2025
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Announces Proposed Public Offering of Common Stock
October 23, 2025
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Congratulates Scientific Advisor Dr. Shimon Sakaguchi for Receiving The Nobel Prize in Physiology or Medicine for Discovery of Regulatory T Cells and Immune Function
October 07, 2025
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Announces Publication of Scientific Research Linking Inflammation and Oxidative Stress to the Progression of Parkinson’s Disease
July 24, 2025
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics to Participate in the BTIG Virtual Biotechnology Conference July 29 – 30, 2025
July 22, 2025
From
Coya Therapeutics, Inc.
Via
Business Wire
Updated Lineup Announced for iAccess Alpha's Virtual Summer Investment Conference, June 24–25, 2025
June 23, 2025
Via
ACCESS Newswire
iAccess Alpha's Virtual Best Ideas Summer Investment Conference June 24-25, 2025
June 18, 2025
Via
ACCESS Newswire
Coya Therapeutics to Present at the iAccess Alpha Virtual Best Ideas Summer Conference on June 24 – 25, 2025
June 18, 2025
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Announces Issuance of New U.S. Patent Protecting Methods of Producing Recombinant Human (rh) Interleukin-2 (aldesleukin) Liquid Formulations
June 02, 2025
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor Conference
May 16, 2025
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Reports First Quarter Financial Results and Provides a Corporate Update
May 13, 2025
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics to Participate in Two Upcoming Conferences in May 2025
May 08, 2025
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Announce Positive Interim Result from Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia
April 24, 2025
Via
Get News
Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia
April 24, 2025
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death)
April 21, 2025
From
Coya Therapeutics, Inc.
Via
Business Wire
Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program
April 17, 2025
Enters into Agreement with Bradley L. Radoff and Michael Torok
From
Atea Pharmaceuticals, Inc.
Via
GlobeNewswire
Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025
April 01, 2025
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome Program
March 26, 2025
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results
March 18, 2025
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics to Participate in KOL Call Hosted by BTIG to Discuss the Potential Treatment of Alzheimer’s Disease Using GLP-1 Agonists and Combinations
February 25, 2025
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimer’s Disease Following Monthly Dosing with Low-Dose IL-2, Further Supporting Clinical Development
February 06, 2025
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 04, 2025
From
Coya Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
